Myomics’ mission is to discover and develop new therapeutics for improving muscle function. Using its patented tissue engineered muscle-based drug screening technology, Myomics can rapidly and accurately discover new drugs intended to improve skeletal muscle performance as well to attenuate skeletal muscle dysfunction in disorders such as sarcopenia, cancer cachexia, and the muscular dystrophies. Compound screening services are provided to numerous pharmaceutical companies, academic centers, and non-profit foundations. In-house efforts are currently focused on discovering and developing small molecule therapeutics for Duchenne Muscular Dystrophy (DMD) for which there are no approved drugs.